Valuation: Structure Therapeutics Inc.

Market Cap 1.97B 1.75B 1.64B 1.49B 2.81B 190B 2.84B 19.8B 7.67B 96.97B 7.41B 7.25B 311B P/E 2026 *
-17.2x
P/E 2027 * -12.9x
Enterprise Value 1.01B 894M 834M 760M 1.43B 96.71B 1.45B 10.1B 3.91B 49.44B 3.78B 3.69B 159B EV / Sales 2026 *
24.1x
EV / Sales 2027 * 31,110x
Free-Float
94.05%
Yield 2026 *
-
Yield 2027 * -
1 day-4.52%
1 week-22.99%
Current month-11.51%
1 month-41.55%
3 months-48.23%
6 months-48.26%
Current year-60.22%
1 week 27.57
Extreme 27.5701
35.64
1 month 27.57
Extreme 27.5701
47.38
Current year 27.57
Extreme 27.5701
94.77
1 year 25.59
Extreme 25.5901
94.9
3 years 13.22
Extreme 13.22
94.9
5 years 13.22
Extreme 13.22
94.9
10 years 13.22
Extreme 13.22
94.9
Manager TitleAgeSince
Director of Finance/CFO 48 30/04/2022
Chief Executive Officer 62 30/04/2019
Chief Operating Officer 49 14/04/2026
Director TitleAgeSince
Director/Board Member 62 31/01/2019
Chairman 68 18/01/2022
Director/Board Member 66 28/03/2022
Date Insider Type Main position Quantity % Market Cap. Importance
21/09/26 Conversion

Chief Technology Officer

-20,040 0.0143%
01/09/26 Exercice

Chief Technology Officer

65,329 0.0467%
18/08/26 Exercice

Chief Technology Officer

43,329 0.0310%
Change 5-day change 1-year change 3-year change Capi.($)
-4.52%-22.99%+1.43%-53.05% 1.97B
+4.16%+3.04%+49.37%+94.17% 74.16B
-3.11%-3.53%+20.19%+81.44% 57.39B
+0.89%-0.63%+2.17%+36.19% 47.64B
+0.36%+0.81%+342.39%+742.40% 44.29B
-0.96%-4.50%+24.96%+35.38% 42.5B
-0.20%-0.77%+4.13%+105.50% 40.71B
-0.54%+2.93%+9.31%+50.41% 30.97B
-2.68%+2.92%+29.33%+22.72% 28.53B
+0.05%-1.64%-8.14%-11.37% 24.34B
Average -0.66%-2.83%+47.51%+110.38% 39.25B
Weighted average by Cap. +0.10%-0.95%+56.68%+137.30%

Financials

2026 *2027 *
Net sales 41.67M 37.02M 34.55M 31.49M 59.4M 4.01B 59.95M 418M 162M 2.05B 156M 153M 6.57B 45.45K 40.38K 37.69K 34.35K 64.79K 4.37M 65.39K 456K 177K 2.23M 171K 167K 7.17M
Net income -314M -279M -260M -237M -447M -30.17B -452M -3.15B -1.22B -15.42B -1.18B -1.15B -49.49B -471M -419M -391M -356M -671M -45.28B -678M -4.73B -1.83B -23.15B -1.77B -1.73B -74.29B
Net Debt -967M -859M -802M -731M -1.38B -92.98B -1.39B -9.71B -3.76B -47.53B -3.63B -3.55B -153B -559M -497M -464M -423M -797M -53.76B -805M -5.61B -2.17B -27.48B -2.1B -2.05B -88.2B
Logo Structure Therapeutics Inc.
Structure Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing oral small molecule treatments for chronic metabolic and cardiopulmonary conditions with significant unmet medical needs. Its programs include Aleniglipron (GSBR-1290), ACCG-2671, GIP and GCG Receptor Oral Small Molecule Obesity Programs, ANPA-0073, and LTSE-2578. Its Aleniglipron is an oral and biased small molecule agonist of GLP-1R, a validated GPCR drug target for obesity. ACCG-2671 is an oral small molecule amylin receptor agonist for obesity. ANPA-0073 is a biased agonist targeting the apelin (APJ) receptor agonist. Its LTSE-2578, an Oral Small Molecule LPA1R Antagonist for IPF. It is developing an antagonist that targets lysophosphatidic acid 1 receptor (LPA1R), a GPCR implicated in responses to tissue injury and pro-fibrotic processes, for the treatment of IPF. It is developing oral incretins for potential combination therapy with GLP-1R or amylin candidates.
Employees
281
Date Price Change Volume
02/10/26 US$27.67 -4.52% 1,715,035
01/10/26 US$28.98 -7.32% 2,592,805
30/09/26 US$31.27 -4.34% 2,197,313
29/09/26 US$32.69 -6.77% 1,728,833
28/09/26 US$35.07 -2.41% 1,282,573
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.67USD
Average target price
105.78USD
Spread / Average Target
+282.30%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. GPCR Stock